Award details

Improving the penicillin fermentation by modelling and optimising its metabolic network and transporterome

Reference	BB/R014744/1
Principal Investigator / Supervisor	Professor Douglas Kell
Co-Investigators / Co-Supervisors
Institution	University of Liverpool
Department	Institute of Integrative Biology
Funding type	Research
Value (£)	428,903
Status	Completed
Type	Research Grant
Start date	01/10/2018
End date	21/07/2022
Duration	46 months

Abstract

Penicillin was famously (re) discovered by Alexander Fleming in 1928, and developed into an initial fermentation process by Florey, Chain and Heatley during the early 1940s. It remains one of the UK fermentation industry's top products. However, in terms of the efficiency of conversion of carbon in the sugar feedstock to carbon in the penicillin product (<10%) it is a lousy fermentation. Many others such as that producing monosodium glutamate, have a carbon conversion efficiency approaching 100%. Consequently, there is much room for improvement, and for making the penicillin process more competitive economically. As with the design of engineering artefacts such as the Boeing 777, what is needed is a mathematical model of the metabolic network of the penicillin producer, P. chrysogenum. The genome sequence is available, and the genes in the production strain are the same; they just differ in expression. To this end, transcriptome data FROM THE PRODUCTION STRAIN ITSELF will be made available by GSK. From this we shall produce a computer version of the metabolic network for analysis. Importantly, the media used for the penicillin process are fully defined, which makes it feasible to do this modelling. From the model, we can predict, initially qualitatively, what molecules it will produce, and these will be measured experimentally on extracts of cells and medium provided by GSK. The combination of the model and the transcriptome allows us to calculate all the fluxes, both to product and to non-profitable places. This will determine which changes in the genetic make-up of the Penicillium fungi are most likely to lead to a higher carbon conversion efficiency. These changes will be made (by GSK) and tested on the new production strains. The use of cell extracts and modelling means that while we have access to the data we do not need access to the proprietary production strains themselves. Importantly, we shall curate all of the data in a suitable database.

Summary

Penicillin was famously (re)discovered by Alexander Fleming in 1928, and developed into an initial fermentation process by Florey, Chain and Heatley during the early 1940s. Despite increasing antimicrobial resistance, it remains one of the UK fermentation industry's top products (often combined with the penicillinase inhibitor clavulanic acid in products such as Augmentin). However, in terms of the efficiency of conversion of carbon in the sugar feedstock to carbon in the penicillin product it is a lousy fermentation as this efficiency is no more than 10%. Many other fermentations, such as that producing monosodium glutamate, have a carbon conversion efficiency approaching 100%. Consequently, there is much room for improvement, and for making the penicillin process more competitive economically. As with the design of engineering artefacts such as the Boeing 777, what is needed is a mathematical model of the metabolic network of the penicillin producer, P. chrysogenum. The amount that each gene is expressed tells us what is going on, and is known as the transcriptome. To this end, transcriptome data FROM THE PRODUCTION STRAIN ITSELF will be made available by GSK. From the (known) genome sequence we can produce a computer version of the metabolic network for analysis. Importantly, the media used for the penicillin process are fully defined, which makes it feasible to do this modelling. Having produced the model, we can predict, initially qualitatively, what molecules it will produce, and these will be measured experimentally on extracts of cells and medium provided by GSK. The combination of the model and the transcriptome allows us to calculate all the fluxes, both to product and to non-profitable places. This will help determine which changes in the genetic make-up of the Penicillium fungi are most likely to lead to a higher carbon conversion efficiency. These changes will be made (by GSK) and tested on the new production strains. The ability to do these analyses on cell extracts and inside a computer means that while we have access to the data we neither have nor need access to the proprietary production strains themselves. Importantly, we shall curate all of the data in a suitable database.

Impact Summary

WHO WILL BENEFIT: The collaborating company will benefit in a number of ways, by (i) gaining access to a full metabolic network model of a producer organism and the predicted fluxes through every node, (ii) understanding which transporters are involved in the main fluxes of substrates and products, (iii) eventually gaining significant economic leverage via improved product titres and carbon conversion efficiencies. So far as industrial biotechnology more generally is concerned, companies will benefit from knowledge of the benefits of our approaches for predictive metabolic engineering. HOW WILL THEY BENEFIT: As is our practice, all pertinent data are made available via the Web, and OA publishing has long been our norm. We also hold frequent workshops in Manchester to assist dissemination of research results. We have pioneered in the Altmetrics field for digital dissemination: indeed, in a recent Nature article (Altmetrics make their mark. Nature 2013; 500:491-492) Kwok highlighted the fact that the PI's paper Hull D, Pettifer SR, Kell DB: Defrosting the digital library: bibliographic tools for the next generation web. PLoS Comput Biol 2008; 4:e1000204, was the most accessed ever in any PLoS journal, with over 53,000 accesses (it is well past 100,000 now). We shall work closely with University KT staff and industrial IP offices (UMIP in Manchester) to agree a mutually beneficial contract as part of this project. Finally, having secured IP, we shall, of course, seek actively to communicate our scientific findings to the wider research community through scientific meetings, scholarly publications and press releases. THE WIDER COMMUNITY: DBK is also a well known blogger and tweeter, and social media will provide a novel and useful means of disseminating our findings. COMMUNICATIONS: We will communicate with relevant industrial partners both directly and via the meetings of relevant learned societies (we are members of several). In year three of the Project, wewill organise a half-day meeting to explain our research to interested industrial scientists. However, we will also provide a video link to facilitate the participation of those who are unable to travel to Manchester.

Committee	Research Committee D (Molecules, cells and industrial biotechnology)
Research Topics	Industrial Biotechnology
Research Priority	X – Research Priority information not available
Research Initiative	LINK: Responsive Mode [2010-2015]
Funding Scheme	X – not Funded via a specific Funding Scheme

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search